

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449/PTO

**(Use as many sheets as necessary)**

**Complete if Known**

Application Number	Unassigned
Filing Date	December 5, 2003
First Named Inventor	Hanns-Wolf BAENKLER
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	STURK0007

Sheet	1	of	2
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

Examiner Signature	/Maureen Wallenhorst/ (04/11/2007)
--------------------	------------------------------------

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete If Known**

Application Number Unassigned

Filing Date December 5, 2003

First Named Inventor Hanns-Wolf BAENKLER

Art Unit Unassigned

Examiner Name Unassigned

Attorney Docket Number STURK0007

Sheet

2

of

2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/MW/	B	BUHLMANN LABORATORIES AG, Equine CAST(R) Cellular Antigen Stimulation Test, Allschwil, Switzerland, December, 2002, pp 1-20.	

Examiner  
Signature

/Maureen Wallenhorst/ (04/11/2007)

Date


Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.




<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number	10/727,568	
				Filing Date	December 5, 2003	
				First Named Inventor	Hanns-Wolf BAENKLER et al	
				Art Unit	Unknown	
				Examiner Name	Unknown	
Sheet	1	of	5	Attorney Docket Number		STURK0007

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/MW/  ↓  /MW/	A	D. Schafer et al, "Effect of Prostaglandin E2 on Eicosanoid Release by Human Bronchial Biopsy Specimens From Normal and Inflamed Mucosa", Thorax, BMJ Publishing Group, GB, Vol. 51, No. 9, September 1996, pps. 919-923.	
	B	P. Mohammadian et al, "A reversible inflammation model in man", Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 353, No. 4. Suppl, 1996, p. r150.	
	C	H.W. Baenkler et al, "Eicosanoids From Biopsy of Normal and Polypous Nasal Mucosa", Rhinology, Leiden, NL, Vol. 34, No. 3, 1996, pps. 166-170.	
	D	D.Schafer et al, "Dynamics of Eicosanoids in Peripheral Blood Cells During Bronchial Provocation in Aspirin-Intolerant Asthmatics", European Respiratory Journal, Munksgaard International Publishers, Copenhagen, DK, Vol. 13, No. 3, March 1999, pps. 638-646.	
	E	P.T. Bozza et al, "Mechanisms of Formation and Function of Eosinophil Lipid Bodies: Inducible Intracellular Sites Involved in Arachidonic Acid Metabolism", Memorias Do Instituto Oswaldo Cruz, Rio De Janeiro, Br, Vol. 92, No. Suppl 2, 1997, pps. 135-140.	
	F	C. Pompeia et al, "Fatty Acids and the Immune System", Revista Brasileira De Ciencias Farmaceuticas - Brazilian Journal of Pharmaceutical Sciences, Faculdade de Ciencias Farmaceuticas, Sao Paulo, BR, Vol. 35, No. 2, 1999, pps. 165-194.	
	G	V.G.S. Hirschberg, "Mitteilung uber einen Fall von Nebenwirkung des Aspirin", Dt Med Wochenschr 1902; Vol. 23, pp. 416.	
	H	U.S. von Euler, "Über die spezifische blutdrucksenkende Substanz des menschlichen Prostata-und Samenblasensekretes", Klin Wschr 1935;14:1182-1185.	
	I	Donald J. Hanahan, "Platelet Activating Factor: A Biologically Active Phosphoglyceride", Ann Rev Biochem, 1986;55: pps. 483-509.	
	J	Mats Hamberg et al, "Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides", Proc. Nat. Acad. Sci. USA 72 (1975) pps. 2994-2998.	

Examiner Signature	/Maureen Wallenhorst/ (04/12/2007)	Date Considered	
--------------------	------------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number	10/727,568	
				Filing Date	December 5, 2003	
				First Named Inventor	Hanns-Wolf BAENKLER et al	
				Art Unit	Unknown	
				Examiner Name	Unknown	
Sheet	2	of	5	Attorney Docket Number		STURK0007

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/MW/	K	J.R. Vane, "Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs", Nature New Biology, Vol. 231, June 23, 1971, pps. 232-235.	
	L	Sune Bergstrom, "Prostaglandins: Members of a New Hormonal System", Science, Vol. 157, 1967, pps. 382-391.	
	M	Bengt Samuelsson, "Some Recent Advances in Leukotriene Research", Adv Exp Med Biol 1997; 433, pps. 1-7.	
	N	Bengt Samuelsson et al, "Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects", Science, Vol. 237, 4 September 1987, pps. 1171-1175.	
	O	Michael J. Holtzman, "Arachidonic Acid Metabolism", Am Rev Respir Dis 1991, Vol. 143, pps. 188-203.	
	P	William L. Smith, "The eicosanoids and their biochemical mechanisms of action", Biochem. J., 1989, Vol. 259, pps. 315-324.	
	Q	Armel Fradin et al, "Platelet-Activating Factor and Leukotriene Biosynthesis in Whole Blood - A Model for the Study of Transcellular Arachidonate Metabolism", The Journal of Immunology, Vol. 143, No. 11, December 1, 1989, pps. 3680-3685.	
	R	D. L. Smith et al, "A Suggested Shorthand Nomenclature for the Eicosanoids", LIPIDS, Vol. 22, No. 12, 1987, pps. 983-986.	
	S	E.J. Corey et al, "Recent Studies on the Chemical Synthesis of Eicosanoids", Adv Prostaglandin Thromboxane Res 1980, Vol. 6, pps. 19-25.	
/MW/	T	A. L. Willis et al, "Metabolism of Arachidonic Acid: An Overview", The Handbook of Immunopharmacology, Lipid Mediators, Ed.: Cunningham F.M., Academic Press, London, 1994, pps. 1-32.	

Examiner Signature	/Maureen Wallenhorst/ (04/12/2007)	Date Considered	
--------------------	------------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/727,568	
			Filing Date	December 5, 2003	
			First Named Inventor	Hanns-Wolf BAENKLER et al	
			Art Unit	Unknown	
			Examiner Name	Unknown	
Sheet	3	of	5	Attorney Docket Number	STURK0007

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/MW/	U	T. F. Slater et al, "Introduction to the eicosanoids", Prostaglandins and related substances, eds.: Benedetto C, McDonald-Gibson RG, Nigam S, Slater TF, IRL Press, Oxford, 1987, pps. 1-4.	
	V	David W. Stanley-Samuelson, "Physiological Roles of Prostaglandins and Other Eicosanoids in Invertebrates", Biol. Bull, Vol. 173, August 1987, pps. 92-109.	
	W	M.V. Bell et al, "The Role of Polyunsaturated Fatty Acids in Fish", Comp. Biochem. Physiol. Vol. 83B, No. 4, 1986, pps. 711-719.	
	X	Edward A. Dennis, "Diversity of Group Types, Regulation, and Function of Phospholipase A2", The Journal of Biological Chemistry, Vol. 269, No. 18, May 6, 1994, pps. 13057-13060.	
	Y	Christophe Creminon et al, "Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclooxygenase expression in human umbilical vein endothelial cells using specific immunometric enzyme immunoassays", Biochimica et Biophysica Acta, Vol. 1254, 1995, pps. 341-348.	
	Z	Gary P. O'Neill et al, "Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues", Federation of European Biochemical Societies, Vol. 330, No. 2, September 1993, pps. 156-160.	
	AA	I. Kennedy et al, "Studies on the Characterisation of Prostanoid Receptors: A Proposed Classification", Prostaglandins, Vol. 24, No. 5, November 1982, pps. 667-689.	
	BB	David L. DeWitt et al, "Serum Glucocorticoid Regulation of Gene Transcription and Expression of the Prostaglandin H Synthase-1 and Prostaglandin H Synthase-2 Isozymes", Archives of Biochemistry and Biophysics" Vol. 306, No. 1, October 1993, pps. 94-102.	
	CC	P.J. Gardiner et al, "Leukotriene Receptors and Their Selective Antagonists", Advances in Prostaglandin, Thromboxane, and Leukotriene Research, Vol. 22, 1994, pps. 49-61.	
/MW/	DD	Ju-Lun Hong et al, "Cigarette smoke-induced bronchoconstriction: cholinergic mechanisms, tachykinins, and cyclooxygenase products", J Appl Physiol, Vol. 78, 1995, pps. 2260-2266.	

Examiner Signature	/Maureen Wallenhorst/ (04/12/2007)	Date Considered	
--------------------	------------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/727,568
				Filing Date	December 5, 2003
				First Named Inventor	Hanns-Wolf BAENKLER et al
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	4	of	5	Attorney Docket Number	STURK0007

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/MW/	EE	Robert A. Coleman et al, "Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes", Pharmacol rev., Vol. 46, No. 2, 1994, pps. 205-229.	
	FF	G.W. Taylor et al; "Measurements of Fatty Acids and Their Metabolites", Lipid Mediators, ed. Cunningham F.M., Academic Press, London, 1994, pps. 33-59.	
	GG	Richard J. Kulmacz et al, "Cyclo-oxygenase: measurement, purification and properties", Prostaglandins and related substances, eds. Benedetto C., McDonald-Gibson R.G., Nigam S., Slater T.F., Oxford University Press, Oxford, 1989, pps. 209-227.	
	HH	Tankred Schewe et al, "Lipoxygenases: measurement, characterization and properties", Prostaglandins and related substances, eds. Benedetto C., McDonald-Gibson R.G., Nigam S., Slater T.F., Oxford University Press, Oxford, 1989, pps. 229-242.	
	II	Jaime Vilaseca et al, "Participation of Thromboxane and Other Eicosanoid Synthesis in the Course of Experimental Inflammatory Colitis", Gastroenterology, Vol. 98, No. 2, 1990, pps. 269-277.	
	JJ	A.L. de Weck, "Cellular Allergen Stimulation Test (CAST) - A New Dimension in Allergy Diagnostics", Allergy Clin Immunol News, Vol. 5, 1993, pps. 9-14.	
	KK	H. W. Baenkler et al, "Eicosanoids from biopsy of normal and polypous nasal mucosa", Rhinology, Vol. 34, 1996, pps. 166-170.	
	LL	S.K. Sauer et al, "Stimulated Prostaglandin E2 Release From Rat Skin, In Vitro", Life Science, Vol. 62, No. 22, 1998, pps. 2045-2055.	
↓	MM	D. Schafer et al, "Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics", European Respiratory Journal, Vol. 13, 1999, pps. 638-646.	
/MW/	NN	Jay Y. Westcott, "The Measurement of Leukotrienes in Human Fluids", Clinical Reviews in Allergy and Immunology, Vol. 17, 1999, pps. 153-177.	

Examiner Signature	/Maureen Wallenhorst/ (04/12/2007)	Date Considered	
--------------------	------------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/727,568
				Filing Date	December 5, 2003
				First Named Inventor	Hanns-Wolf BAENKLER et al
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	5	of	5	Attorney Docket Number	STURK0007

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/MW/	OO	Phillip Greenspan et al, "Nile Red: A Selective Fluorescent Stain for Intracellular Lipid Droplets", The Journal of Cell Biology, Vol. 100, March 1985, pps. 965-973.	
↓	PP	Ann M. Dvorak et al, "Lipid Bodies: Cytoplasmic Organelles Important to Arachidonate Metabolism in Macrophages and Mast Cells", The Journal of Immunology, Vol. 131, No. 6, December 1983, pps. 2965-2976.	
↓	QQ	Peter F. Weller et al, "Arachidonic Acid Incorporation by Cytoplasmic Lipid Bodies of Human Eosinophils", Blood, Vol. 65, No. 5, May 1985, pps. 1269-1274.	
/MW/	RR	International Search Report, completed 19 September 2002 (4 pages).	

Examiner Signature	/Maureen Wallenhorst/ (04/12/2007)	Date Considered	
--------------------	------------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.